Shareprice
13 Jul 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

FluoGuide A/S interview by BioStock Live now available

News


April 29, 2020

BioStock Lives interview with FluoGuide is now published. The presentation FluoGuide A/S (“FluoGuide” or “the Company”) did last week is available at BioStock Live and at FluoGuide’s respective webpages. The interview was made by Morten Albrechtsen, CEO, and Andreas Kjaer, CSO. FluoGuide is right now in the middle of the exercise period for the warrants of series TO 1 that was issued in connection with FluoGuide’s issue of units, prior to listing on Spotlight Stock Market. The exercise period runs until and including 7 May 2020. Upon full exercise of all warrants of series TO 1, FluoGuide will be allocated approximately DKK 6.4 million (before costs).

To watch the interview and presentation, please follow link. (https://fluoguide.com/investor/calendar-events/)

For more information regarding the exercise period of warrants – please follow link. (https://fluoguide.com/investor/filings-reports/)